SEC Form 4 · accession 0001387131-16-005715
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eddie Wabern Glover
Officer — CEO of U.S. Compounding, Inc.
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 5:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.46 | May 25, 2016 | A | 70,000 | A | — | May 25, 2026 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1This option vests and becomes exercisable as to one-sixth of the option shares on the six-month anniversary of the grant date, and thereafter as to 1/36 of the option shares on each monthly anniversary of the grant date commencing with the seven-month anniversary of the grant date.